Analyzing Cell MedX (OTCMKTS:CMXC) and Ainos (OTCMKTS:AIMD)

Ainos (OTCMKTS:AIMD) and Cell MedX (OTCMKTS:CMXC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Profitability

This table compares Ainos and Cell MedX’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-515.80%	-44.32%	-40.35%
Cell MedX	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Ainos and Cell MedX, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
Cell MedX	0	0	0	0	N/A

Insider & Institutional Ownership

0.3% of Ainos shares are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Comparatively, 32.4% of Cell MedX shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ainos and Cell MedX’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$122,112.00	54.84	-$14.01 million	($2.55)	-0.43
Cell MedX	N/A	N/A	N/A	($0.01)	-2.91

Cell MedX has lower revenue, but higher earnings than Ainos. Cell MedX is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Summary

Cell MedX beats Ainos on 5 of the 8 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Cell MedX

Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is headquartered in Carson City, Nevada.